Cullinan Therapeutics’ (CGEM) “Overweight” Rating Reaffirmed at Morgan Stanley
Morgan Stanley reissued their overweight rating on shares of Cullinan Therapeutics (NASDAQ:CGEM – Free Report) in a research ...
Cullinan Therapeutics assumed with an Overweight at Morgan Stanley
Morgan Stanley assumed coverage of Cullinan Therapeutics (CGEM) with an Overweight rating and a price target of $35, down from $38. The firm ...
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI), Disc Medicine (IRON) and PTC Therapeutics (PTCT)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Denali Therapeutics (DNLI – Research Report), ...
Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...
Cullinan Therapeutics (CGEM) to Release Quarterly Earnings on Thursday
Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Cullinan Therapeutics to post earnings ...